ArriVent Pharmaceuticals Science
Programs
CandidateCand
IndicationInd
DiscoveryDisc
PreclinicalPre
Phase 1Ph1
Phase 2Ph2
Phase 3Ph3
PartnersPart

Furmonertinib

Oral, brain penetrant, EGFR mutation selective inhibitor

Furmonertinib

Oral, brain penetrant, EGFR mutation selective inhibitor

ARR-002

Undisclosed

ARR-002

Undisclosed